论文部分内容阅读
目的:探讨连花清瘟胶囊在社区病毒性感冒治疗中的疗效。方法:选取2013年1月到2014年4月我社区收治的113例病毒性感冒患者作为本次研究的对象,并将其随机分为对照组(n=56例)与观察组(n=57例)。观察组给予连花清瘟胶囊治疗,对照组给予感冒片治疗,对比两组治疗总效率及其不良反应。结果:观察组采用连花清瘟治疗后,总有效率为94.74%,明显高于对照组(78.57%)(X2=4.125,P=0.042)。观察组57例患者中出现3例出现胃肠道反应,其不良反应发生率为5.26%;对照组56例患者中有2例患者出现胃肠道反应,其不良反应发生率为3.57%,两组比较无明显差异(X2=0.077,P=0.782)。结论:连花清瘟胶囊的疗效显著、安全性好,可以作为治疗病毒性感冒的一线药物。
Objective: To investigate the efficacy of Lianhua Qingwen Capsule in the treatment of community-based viral influenza. Methods: A total of 113 patients with viral influenza who were admitted to our community from January 2013 to April 2014 were selected as the study subjects and randomly divided into control group (n = 56) and observation group (n = 57) example). The observation group was treated with Lianhua Qingwen Capsule, while the control group was treated with cold tablets. The total treatment efficiency and adverse reactions were compared between the two groups. Results: After treatment with Lianhuaqingwen in the observation group, the total effective rate was 94.74%, which was significantly higher than that of the control group (78.57%) (X2 = 4.125, P = 0.042). In the 57 cases of observation group, 3 cases appeared gastrointestinal reactions, the incidence of adverse reactions was 5.26%; control group 56 patients in 2 patients gastrointestinal reactions, the incidence of adverse reactions was 3.57%, two There was no significant difference between groups (X2 = 0.077, P = 0.782). Conclusion: Lianhua Qingwen Capsule has significant curative effect and good safety. It can be used as first-line medicine for treating viral influenza.